[go: up one dir, main page]

ZA991408B - Orally administrable immediate-release and prolonged-release galenic form comprising an absorption-promoting agent and use of this absorption-promoting agent. - Google Patents

Orally administrable immediate-release and prolonged-release galenic form comprising an absorption-promoting agent and use of this absorption-promoting agent.

Info

Publication number
ZA991408B
ZA991408B ZA9901408A ZA991408A ZA991408B ZA 991408 B ZA991408 B ZA 991408B ZA 9901408 A ZA9901408 A ZA 9901408A ZA 991408 A ZA991408 A ZA 991408A ZA 991408 B ZA991408 B ZA 991408B
Authority
ZA
South Africa
Prior art keywords
absorption
release
promoting agent
prolonged
orally administrable
Prior art date
Application number
ZA9901408A
Other languages
English (en)
Inventor
Olivier Saslawski
Philippe Giet
Dominique Michel
Thierry Hulot
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ZA991408B publication Critical patent/ZA991408B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Addiction (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA9901408A 1998-02-23 1999-02-22 Orally administrable immediate-release and prolonged-release galenic form comprising an absorption-promoting agent and use of this absorption-promoting agent. ZA991408B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9802143A FR2775188B1 (fr) 1998-02-23 1998-02-23 Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption

Publications (1)

Publication Number Publication Date
ZA991408B true ZA991408B (en) 1999-08-23

Family

ID=9523244

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9901408A ZA991408B (en) 1998-02-23 1999-02-22 Orally administrable immediate-release and prolonged-release galenic form comprising an absorption-promoting agent and use of this absorption-promoting agent.

Country Status (27)

Country Link
US (2) US6426087B1 (xx)
EP (2) EP1056445B1 (xx)
JP (1) JP4828020B2 (xx)
KR (1) KR100587181B1 (xx)
CN (1) CN1182837C (xx)
AP (1) AP2000001943A0 (xx)
AR (2) AR018109A1 (xx)
AT (2) ATE268164T1 (xx)
AU (1) AU750785B2 (xx)
BR (1) BR9908121A (xx)
CA (1) CA2321267C (xx)
CZ (1) CZ299366B6 (xx)
DE (2) DE69939605D1 (xx)
DK (2) DK1410791T3 (xx)
ES (2) ES2222695T3 (xx)
FR (1) FR2775188B1 (xx)
HU (1) HU226732B1 (xx)
ID (1) ID26022A (xx)
NO (1) NO20004190L (xx)
OA (1) OA11454A (xx)
PL (2) PL191415B1 (xx)
PT (2) PT1410791E (xx)
RU (1) RU2228201C2 (xx)
SI (2) SI1410791T1 (xx)
SK (2) SK285188B6 (xx)
WO (1) WO1999042086A1 (xx)
ZA (1) ZA991408B (xx)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925127D0 (en) * 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
FR2805462B1 (fr) * 2000-02-24 2003-08-15 Therabel Res Nouvelle forme galenique orale a liberation prolongee de la molsidomine
DE10026699A1 (de) 2000-05-30 2001-12-06 Basf Ag Formulierung auf Heparin-, Glycosaminoglycan- oder Heparinoidbasis und Verwendung der Formulierung sowie der Formulierungsgrundlage
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
SE0200475D0 (sv) * 2002-02-15 2002-02-15 Ltp Lipid Technologies Provide Oral farmaceutisk beredning
EP1499306A4 (en) 2002-04-12 2007-03-28 Merck & Co Inc BICYCLIC AMIDE
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
US10004729B2 (en) 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
FR2845289B1 (fr) * 2002-10-04 2004-12-03 Ethypharm Sa Spheroides, procede de preparation et compositions pharmaceutiques.
AU2003282498A1 (en) * 2002-10-07 2004-05-04 Chiron Corporation Hiv vaccine formulations
US20040151769A1 (en) * 2002-12-31 2004-08-05 Boehringer Ingelheim International Gmbh Film coated tablet containing an extract of red vine leaves
ITRM20030074A1 (it) * 2003-02-21 2004-08-22 Pharmacia Italia Spa Formulazioni semisolide a rilascio immediato intese
US20040241252A1 (en) * 2003-05-29 2004-12-02 Abney Christopher Charles Pharmaceutical compositions for oral administration comprising lithium carbonate, processes of making the same, and methods of administering the same
RU2241449C1 (ru) * 2003-09-25 2004-12-10 Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" Фармацевтическая композиция для лечения диабета (варианты)
WO2005060942A1 (en) * 2003-12-19 2005-07-07 Aurobindo Pharma Ltd Extended release pharmaceutical composition of metformin
BRPI0510074A (pt) * 2004-04-22 2007-10-16 Boehringer Ingelheim Int composições farmacêuticas para o tratamento de distúrbios sexuais ii
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
US20080181946A1 (en) * 2004-05-14 2008-07-31 Braj Bhushan Lohray Controlled Release Delivery System For Metformin
EP3326617A1 (en) 2004-06-12 2018-05-30 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
US20060024370A1 (en) * 2004-07-29 2006-02-02 Cephalon France Modafinil oral lyophilizate
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
CA2576812A1 (en) * 2004-09-03 2006-03-09 Boehringer Ingelheim International Gmbh Method for the treatment of attention deficit hyperactivity disorder
WO2006038134A1 (en) * 2004-10-01 2006-04-13 Firmenich Sa Perfuming or flavouring microcapsules comprising an explosion suppressant
EP1858515A2 (en) * 2005-03-04 2007-11-28 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
JP2008538741A (ja) * 2005-03-04 2008-11-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 鬱病の治療用及び／又は予防用の医薬組成物
UY29445A1 (es) * 2005-03-30 2006-10-02 Generex Pharm Inc Composiciones para la transmisión transmucosa oral de la metformina
JP2008540356A (ja) * 2005-05-06 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬物乱用の治療方法
CA2608363A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of drug-induced sexual dysfunction
EP1888070A1 (en) * 2005-05-19 2008-02-20 Boehringer Ingelheim International GmbH Method for the treatment of sexual dysfunctions due to medical conditions
KR101306088B1 (ko) * 2005-06-21 2013-09-09 메르크 파텐트 게엠베하 (ｒ)-(-)-２-[５-(４-플루오로페닐)-３-피리딜-메틸아미노메틸]크로만을 함유하는 고형 약제학적 조성물
EP1745788A1 (de) * 2005-07-22 2007-01-24 KTB Tumorforschungsgesellschaft mbH Acylglycerophospholipide zur Behandlung von Krebs und Tumorkachexie
JP2009503020A (ja) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症の治療におけるフリバンセリンの使用
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
JP2009513604A (ja) * 2005-10-29 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 月経前障害及び他の女性の性的障害治療用のベンゾイミダゾロン誘導体
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
WO2007106957A1 (en) * 2006-03-21 2007-09-27 Laboratoires Smb S.A. Multiple units controlled-release floating dosage forms
KR20090005371A (ko) * 2006-05-09 2009-01-13 베링거 인겔하임 인터내셔날 게엠베하 폐경후 성욕 장애의 치료를 위한 플리반세린의 용도
WO2008000760A1 (en) 2006-06-30 2008-01-03 Boehringer Ingelheim International Gmbh Flibanserin for the treatment of urinary incontinence and related diseases
CA2657043A1 (en) * 2006-07-14 2008-01-17 Boehringer Ingelheim International Gmbh Use of flibanserin for the treatment of sexual disorders in females
MX2009001551A (es) * 2006-08-14 2009-02-20 Boehringer Ingelheim Int Formulaciones de flibanserina y metodo para fabricarlas.
CL2007002214A1 (es) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
WO2008022932A2 (en) * 2006-08-25 2008-02-28 Boehringer Ingelheim International Gmbh Controlled release system and method for manufacturing the same
US20080078498A1 (en) * 2006-10-03 2008-04-03 Zeik Douglas B Articles and methods for applying color on surfaces
EP1952803A1 (en) 2007-01-23 2008-08-06 KTB-Tumorforschungs GmbH Solid pharmaceutical dosage form containing hydrogenated phospholipids
WO2009033079A1 (en) * 2007-09-07 2009-03-12 Xenoport, Inc. Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
TW200924746A (en) * 2007-09-07 2009-06-16 Xenoport Inc Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
UY31335A1 (es) * 2007-09-12 2009-04-30 Tratamiento de sintomas vasomotores
EP2042165A1 (de) * 2007-09-28 2009-04-01 Swiss Caps Rechte und Lizenzen AG Hot-Melt-Befüllte Weichkapseln
TW200932734A (en) * 2007-10-15 2009-08-01 Xenoport Inc Internally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
CA2638240C (en) * 2008-08-29 2010-02-02 Alexander Macgregor Method of treating dysglycemia and glucose excursions
EP2370060B1 (en) 2008-11-27 2017-05-03 B.R.A.I.N. Biotechnology Research and Information Network AG Hydrophobins as surface active proteins as excipients in solid pharmaceutical formulations
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
EP2512455B8 (en) 2009-12-18 2014-07-23 FrieslandCampina Nederland Holding B.V. Co-processed tablet excipient composition its preparation and use
JP5546900B2 (ja) * 2010-02-25 2014-07-09 ライオン株式会社 パナキサトリオール安定化組成物
HK1199841A1 (en) * 2010-05-18 2015-07-24 Synchroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
EP2621487B1 (en) * 2010-09-28 2017-05-03 Depomed, Inc. Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
US20130143867A1 (en) * 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
KR20180021932A (ko) * 2013-03-15 2018-03-05 아이슈티카 인코포레이티드 아비라테론 아세테이트 제제
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
CA2914365C (en) 2013-06-05 2022-03-15 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
US12042566B2 (en) 2017-05-17 2024-07-23 Confluence Pharmaceuticals, Llc Formulations of homotaurines and salts thereof
US20240350414A1 (en) 2021-08-25 2024-10-24 Basf Se Direct tableting auxiliary composition

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI63335B (fi) * 1979-02-02 1983-02-28 Orion Yhtymae Oy Foerfarande foer framstaellning av tabletter med foerdroejd loslighet av effektaemne
FR2457281A1 (fr) * 1979-05-23 1980-12-19 Meram Lab Nouveaux derives de l'acide 3-aminopropanesulfonique ayant une activite membranaire renforcee
GB8524421D0 (en) * 1985-10-03 1985-11-06 Boots Co Plc Therapeutic agents
JPS62265226A (ja) * 1986-05-12 1987-11-18 Fujisawa Pharmaceut Co Ltd 経口投与用製剤
ZA898331B (en) * 1988-11-22 1990-07-25 Hoffmann La Roche Pharmaceutical compositions
US5190748A (en) * 1988-11-22 1993-03-02 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
US5139786A (en) * 1989-07-07 1992-08-18 Ciba-Geigy Corporation Topical formulations
JPH03275633A (ja) * 1990-03-23 1991-12-06 Teikoku Seiyaku Co Ltd 生理活性ポリペプチドの吸収促進剤
US5138786A (en) 1991-07-17 1992-08-18 Fischer Michael G Insta-guard firearm protection
IT1255895B (it) * 1992-10-20 1995-11-17 Laura Chiodini Composizioni farmaceutiche contenenti una calcitonina
DE4432757A1 (de) * 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
US5858398A (en) * 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
JP3275633B2 (ja) 1995-06-16 2002-04-15 松下電器産業株式会社 脱水兼用洗濯機
GB9516268D0 (en) * 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon

Also Published As

Publication number Publication date
HK1035142A1 (en) 2001-11-16
EP1410791A1 (en) 2004-04-21
FR2775188B1 (fr) 2001-03-09
AU750785B2 (en) 2002-07-25
ATE408399T1 (de) 2008-10-15
RU2228201C2 (ru) 2004-05-10
DK1410791T3 (da) 2009-01-12
JP4828020B2 (ja) 2011-11-30
CZ299366B6 (cs) 2008-07-02
ATE268164T1 (de) 2004-06-15
DK1056445T3 (da) 2004-10-04
SK285188B6 (sk) 2006-08-03
SK12552000A3 (sk) 2001-02-12
ES2314302T3 (es) 2009-03-16
CN1182837C (zh) 2005-01-05
US6426087B1 (en) 2002-07-30
CZ20002940A3 (cs) 2000-11-15
AR018109A1 (es) 2001-10-31
CN1291091A (zh) 2001-04-11
EP1410791B1 (en) 2008-09-17
HUP0100970A2 (hu) 2001-08-28
ID26022A (id) 2000-11-16
PT1410791E (pt) 2008-12-24
WO1999042086A1 (en) 1999-08-26
PT1056445E (pt) 2004-10-29
KR100587181B1 (ko) 2006-06-08
EP1056445B1 (en) 2004-06-02
FR2775188A1 (fr) 1999-08-27
OA11454A (en) 2003-12-08
EP1056445A1 (en) 2000-12-06
SI1056445T1 (en) 2004-10-31
NO20004190L (no) 2000-10-20
PL342162A1 (en) 2001-05-21
KR20010034537A (ko) 2001-04-25
AP2000001943A0 (en) 2000-12-31
HU226732B1 (en) 2009-08-28
AU3140899A (en) 1999-09-06
US6514524B1 (en) 2003-02-04
CA2321267C (en) 2007-04-17
PL201851B1 (pl) 2009-05-29
DE69917750T2 (de) 2005-05-25
AR066843A2 (es) 2009-09-16
SK286248B6 (sk) 2008-06-06
BR9908121A (pt) 2000-10-24
PL191415B1 (pl) 2006-05-31
JP2002503686A (ja) 2002-02-05
DE69939605D1 (de) 2008-10-30
CA2321267A1 (en) 1999-08-26
DE69917750D1 (de) 2004-07-08
ES2222695T3 (es) 2005-02-01
NO20004190D0 (no) 2000-08-22
WO1999042086A9 (en) 2000-08-31
HUP0100970A3 (en) 2001-12-28
SI1410791T1 (sl) 2009-02-28

Similar Documents

Publication Publication Date Title
ZA991408B (en) Orally administrable immediate-release and prolonged-release galenic form comprising an absorption-promoting agent and use of this absorption-promoting agent.
EG23821A (en) Oral pharmaceutical dosage forms comprising a protom pump inhibitor and an antacid agent or alginate
BR9912979B1 (pt) composição farmacêutica administrável oralmente, tablete de mascar, cápsula e uso de chitosan.
IL137445A0 (en) Pharmaceutically active compounds and methods of use thereof
IL131201A0 (en) Pharmaceutical formulations comprising amoxocyllin and clavulanate
ZA993200B (en) Use of nanodispersions in pharmaceutical end formulations.
IL141155A0 (en) Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin
HUP9903613A3 (en) Improvement in the taste of active pharmaceutical ingredients
ZA200108260B (en) A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate.
EP1372739A4 (en) STABILIZED THERAPEUTIC AND IMAGING AGENTS
MXPA02003174A (es) Combinacion novedosa de loteprednol y antihistaminicos.
EP1115396A4 (en) PHARMACEUTICALLY ACTIVE COMPOUNDS, AND METHODS OF USE THEREOF
SI1183026T1 (sl) Izboljsane farmacevtske spojine, vsebujoce ritonavir
WO1998038983A3 (en) Swallow tablet comprising paracetamol
NZ513650A (en) Pharmaceutical composition for the treatment of urinary incontinence, motion sickness and vertigo
AU1164601A (en) Therapeutic use and formulation
AU2001264044A1 (en) 1,4-diazabicyclo(3.2.2)nonabenzoxazole, -benzothiazole and benzimidazole derivatives, preparation and therapeutic use thereof
IL125913A0 (en) Pharmaceutical combination preparation of an inhibitor of the sodium/hydrogen exchanger and medicament for the treatment of cardio-vascular diseases
MXPA03001752A (es) Uso de la combinacion de salmeterol y propionato de fluticasona.
NO20001717D0 (no) Serotonin-inneholdende formulering for oral administrering og anvendelse av samme
ZA981354B (en) Aqueous pharmaceutical composition comprising an active ingredient which is highly insoluble in water
ZA977957B (en) Pharmacologically active compounds and use.
HUP0003074A3 (en) Pharmaceutical composition comprising ssri and betha-blocking agent
HUP0105351A3 (en) Effervescent laxatives and their use
HU0800735D0 (hu) Orálisan adagolható, azonnali és nyújtott hatóanyag-felszabadítású, felszívódást elõsegítõ szert tartalmazó galenusi készítmény és ezen felszívódást elõsegítõ szer alkalmazása